# IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA NORFOLK DIVISION

# IN RE ZETIA (EZETIMIBE) ANTITRUST LITIGATION

MDL No. 2:18-md-2836



THIS DOCUMENT RELATES TO:

ALL ACTIONS

# JOINTLY PROPOSED PRETRIAL ORDER NO. 5

Pursuant to this Court's Pretrial Order No. 4 (PTO 4),<sup>1</sup> the parties to the above-referenced actions, through their respective counsel, hereby jointly stipulate as follows with respect to (1) a complete pretrial schedule, (2) number of depositions, (3) number of interrogatories, and (4) number of requests for admissions.

## 1. Pretrial Schedule

The parties shall adhere to the agreed upon dates in the following schedule. Should any future modification to the schedule become necessary in the view of any party, the parties shall confer and submit a request to the Court to amend the schedule on a joint or opposed basis, as appropriate.

Event	Date
Deadline for Direct Purchaser Plaintiffs ("DPPs") and End- Payer Plaintiffs ("EPPs") to file consolidated complaints; Retailers to file amended complaint, if desired (PTO 4, Dkt. No. 106)	September 13, 2018

<sup>&</sup>lt;sup>1</sup> ECF No. 106.

Event	Date
Submission of Proposed Pretrial Schedule (PTO 4, Dkt. No. 106)	October 1, 2018
Defendants answer or otherwise move in response to DPP and EPP consolidated complaints as well as Retailer complaints (PTO 4, Dkt. No. 106)	October 11, 2018
Service of Rule 26(a) Disclosures	October 15, 2018
Deadline for Defendants to produce document productions made in connection with underlying, Zetia-related patent litigation, <sup>2</sup> as well as any productions made in connection with any Federal Trade Commission or Congressional investigation or litigation, that Defendants have located by the date specified for this early production (should any such productions be requested and discoverable under the Federal Rules of Civil Procedure and subject to Defendants' objections to such requests).	November 12, 2018
Deadline for Initial Rule 33 Interrogatories and Rule 34 Document Requests. Initial paper discovery may be served in advance of this deadline. If that occurs, the responding	October 19, 2018

<sup>&</sup>lt;sup>2</sup> Such actions are Schering Corporation, et al. v. Glenmark Pharmaceuticals Inc., et al., C.A. No. 2:07-cv-01334 (D.N.J.); Schering Corporation, et al., v. Mylan Pharmaceuticals Inc. et al., C.A. No. 2:10-cv-03085 (D.N.J.); Schering Corporation, et al., v. Teva Pharmaceuticals USA, Inc., C.A., No. 2:10-cv-04473 (D.N.J.); and Merck Sharp & Dohme Corp., et al. v. Sandoz Inc., C.A. No. 2:12-cv-06077 (D.N.J.).

Event	Date
party shall not be required to respond before the time allowed by the Federal Rules, or October 19, 2018, whichever is later. <sup>3</sup>	
Submission of Protective Order and ESI Order/Position Papers on Disputed Issues	October 19, 2018
Plaintiffs <sup>4</sup> to file oppositions to any Rule 12 motion(s) (PTO 4, Dkt. No. 106)	November 1, 2018
Defendants shall reply to Plaintiffs' oppositions to Rule 12 motion(s) (PTO 4, Dkt. No. 106)	November 16, 2018
Deadline for parties to produce transaction level data, subject to the parties reaching agreement on content, scope, and time period.	December 14, 2018
Substantial completion of documents responsive to initial Rule 34 Document Requests.	April 22, 2019
Deadline for any supplemental Rule 33 Interrogatories and Rule 34 Document Requests,	May 6, 2019

<sup>&</sup>lt;sup>3</sup> In propounding these initial requests, the parties shall attempt to be as comprehensive as possible.

<sup>&</sup>lt;sup>4</sup> The term "Plaintiffs" as used herein means DPPs, EPPs, and Retailer plaintiffs. In the event that any additional Plaintiffs are added to this MDL proceeding, they shall be included within the definition of the term "Plaintiffs" and bound by this schedule.

Event	Date
and Rule 36 Requests for Admissions <sup>5</sup>	
Parties provide final privilege logs for documents produced in response to initial Rule 34 Document Requests. The parties will work in good faith to produce privilege logs for documents reviewed and identified earlier in the production in advance of the deadline, and thus anticipate producing logs on a rolling basis.	June 7, 2019
Deadline for filing discovery motions and privilege challenges.	July 16, 2019
Fact Discovery closes	August 1, 2019
Deadline to seek leave to amend the complaint(s) and/or add parties	September 16, 2019
DPPs and EPPs move for class certification and disclose expert reports on which they rely for class certification. <sup>6</sup>	August 5, 2019
Defendants oppose class certification and serve expert reports on which they rely in	September 30, 2019

<sup>&</sup>lt;sup>5</sup> Requests for admissions pertaining solely to the authenticity of documents/admissibility of documents for use at trial shall be exempt from this deadline.

<sup>&</sup>lt;sup>6</sup> At the time Plaintiffs serve their expert reports they intend to rely upon for purposes of class certification, they will provide three available dates that would allow Defendants to depose such experts sufficiently in advance of the due date for Defendants' opposition(s) to Plaintiffs' motions.

<b>Event</b> opposition to class certification. <sup>7</sup>	Date
DPPs and EPPs file replies in support of class certification and supporting reply expert reports. <sup>8</sup>	November 5, 2019
Class certification hearing	Early December, 2019
Plaintiffs disclose any merits experts required to be disclosed under Rule 26(a)(2) <sup>9</sup>	September 30, 2019
Defendants disclose any merits experts required to be disclosed under Rule 26(a)(2) 10	November 6, 2019
Plaintiffs serve rebuttal merits expert reports, if any.	November 26, 2019
Deadline for deposing any merits experts disclosed pursuant to Rule 26(a)(2)	December 20, 2019

<sup>&</sup>lt;sup>7</sup> At the time Defendants serve their expert reports they intend to rely upon for purposes of opposing class certification, they will provide three available dates that would allow Plaintiffs to depose such experts sufficiently in advance of the due date for Plaintiffs' replies.

<sup>&</sup>lt;sup>8</sup> Plaintiffs' reply class certification expert reports shall respond to Defendants' class certification expert reports.

<sup>&</sup>lt;sup>9</sup> At the time Plaintiffs serve any additional expert reports pursuant to Rule 26(a)(3), they will provide three available dates that would allow Defendants to depose such experts sufficiently in advance of the due date for Defendants' reports.

<sup>&</sup>lt;sup>10</sup> At the time Defendants serve any additional expert reports pursuant to Rule 26(a)(3), they will provide three available dates that would allow Plaintiffs to depose such experts by the deadline to depose any non-class certification experts.

Event	Date
Deadline for filing Rule 56 and <i>Daubert</i> motions <sup>11</sup>	January 21, 2020
Deadline for filing Rule 56 and <i>Daubert</i> oppositions	February 21, 2020
Deadline for filing Rule 56 and <i>Daubert</i> replies	March 20, 2020
Hearing on Rule 56 and <i>Daubert</i> motions	Late March/Early April 2020
Parties exchange Rule 26(a)(3) disclosures	March 29, 2020
Parties serve objections to Rule 26(a)(3) disclosures	April 10, 2020
Parties file motions in <i>limine</i>	April 24, 2020
Oppositions to motions in <i>limine</i>	May 8, 2020
Attorneys conference	May 20, 2020
Proposed Draft of Pretrial Order Served	June 3, 2020
Parties file proposed voir dire, jury instructions, trial briefs, and witness summaries.	June 17, 2020
Final pre-trial conference	

<sup>&</sup>lt;sup>11</sup> In the event of a summary judgment motion or *Daubert* motion filed before the deadline, briefing on such motions shall proceed in accordance with E.D. Va. Local Rule 7(F)(1) unless otherwise agreed or ordered.

Event	Date
	A day during the week of June 22, 2020
Trial Date	
	July 6, 2020

## 2. Number of Depositions

Each side shall be allowed to take 25 fact depositions of parties, employees, former employees and outside counsel of parties, with DPPs, EPPs, and Retailer plaintiffs grouped together on one side and the Merck and Glenmark Defendants grouped together on the other.

Each side shall be allowed to take 15 non-party depositions, pursuant to Federal Rule of Civil Procedure 45.

Notwithstanding the foregoing, the parties reserve the right to seek leave of the Court to increase the number of depositions.

The above caps do not apply to expert depositions.

# **3.** Number of Interrogatories

Each side shall be allowed to serve 30 interrogatories, with DPPs, EPPs, and Retailer plaintiffs grouped together on one side and the Merck and Glenmark Defendants grouped together on the other. Notwithstanding the foregoing, the parties reserve the right to seek leave of the Court to increase the number of interrogatories, either by stipulation or for good cause shown.

### 4. Number of Requests for Admission

Each side shall be allowed to serve 25 requests for admission ("RFAs") with DPPs, EPPs, and Retailer plaintiffs grouped together on one side and the Merck and Glenmark Defendants grouped together on the other. Notwithstanding the foregoing, the parties reserve the right to seek leave of the Court to increase the number of RFAs, either by stipulation or for good cause shown. The 25 RFA limit shall not include requests for admission going solely to the

authenticity or admissibility of documents.

IT IS SO STIPULATED, through counsel of record

SO ORDERED.

Dated: 0000 2, 2018

pern) 50

**Chief Judge Rebecca Beach Smith** 

/s/ William H. Monroe, Jr. William H. Monroe, Jr. (VSB No. 27441) Marc C. Greco (VSB No. 41496) Kip A. Harbison (VSB No. 38648) Richard S. Glasser (VSB No. 4092) Michael A. Glasser (VSB No. 17651) Glasser and Glasser, P.L.C. Crown Center, Suite 600 580 East Main Street Norfolk, VA 23510 Telephone: (757) 625-6787 Facsimile: (757) 625-5959 bill@glasserlaw.com marcg@glasserlaw.com kip@glasserlaw.com richardg@glasserlaw.com michael@glasserlaw.com

Liaison Counsel for Plaintiff FWK Holdings, LLC, Cesar Castillo, Inc, Rochester Drug Cooperative, Inc. and the Proposed Direct Purchaser Class

> Thomas M. Sobol Kristen A. Johnson Edward Notargiacomo Hannah Schwarzschild Bradley Vettraino Hagens Berman Sobol Shapiro LLP 55 Cambridge Parkway, Suite 301 Cambridge, MA 02142 Tel.: (617) 482-3700 Fax: (617) 482-3003

tom@hbsslaw.com kristenj@hbsslaw.com ed@hbsslaw.com hannahs@hbsslaw.com bradleyv@hbsslaw.com

Counsel for Plaintiff FWK Holdings, LLC, and Lead Counsel for the Proposed Direct Purchaser Class

John D. Radice Radice Law Firm, P.C. 34 Sunset Blvd Long Beach, NJ 08008 Telephone: (646) 245-8502 Facsimile: (609) 385-0745 jradice@radicelawfirm.com Steve D. Shadowen Matthew C. Weiner Hilliard & Shadowen LLP 2407 S. Congress Ave, Suite E 122 Austin, TX 78704 Telephone: (855) 344-3298 steve@hilliardshadowenlaw.com matt@hilliardshadowenlaw.com

Joseph M. Vanek David P. Germaine Jeffrey R. Moran John P. Bjork Vanek, Vickers & Masini, P.C. 55 W. Monroe, Suite 3500 Chicago, IL 60603 Telephone: (312) 224-1500 jvanek@vaneklaw.com dgermaine@vaneklaw.com jmoran@vaneklaw.com jbjork@vaneklaw.com

Paul E. Slater Matthew T. Slater Sperling & Slater, P.C. 55 W. Monroe, Suite 3200 Chicago, IL 60603 Telephone: (312) 641-3200 pes@sperling-law.com mslater@sperling-law.com Joseph H. Meltzer Terence S. Ziegler Kessler Topaz Meltzer & Check LLP 280 King of Prussia Road Radnor, PA 19087 Telephone: 610-667-7706 Facsimile: 610-667-7056 jmeltzer@ktmc.com tziegler@ktmc.com

Counsel for Plaintiff FWK Holdings, LLC and the Proposed Direct Purchaser Class

Linda P. Nussbaum NUSSBAUM LAW GROUP, P.C. 1211 Avenue of the Americas, 40th Floor New York, NY 10036-8718 Tel: (917) 438-9189 Inussbaum@nussbaumpc.com Counsel for Plaintiff Cesar Castillo, Inc. and the Proposed Direct Purchaser Class

David F. Sorensen Zachary D. Caplan BERGER & MONTAGUE, P.C. 1818 Market Street, Suite 3600 Philadelphia, PA 19103 Tel: (215) 875-3000 Fax: (215) 875-4604 dsorensen@bm.net zcaplan@bm.net

Peter R. Kohn Joseph T. Lukens FARUQI & FARUQI, LLP 101 Greenwood Ave, Suite 600 Jenkintown, PA 19046 Tel: (215) 277-5770 Fax: (215) 277-5771 pkohn@faruqilaw.com jlukens@faruqilaw.com Barry Taus Archana Tamoshunas Kevin Landau TAUS, CEBULASH & LANDAU, LLP 80 Maiden Lane, Suite 1204 New York, NY10038 Tel: (646) 873-7654 btaus@tcllaw.com atamoshunas@tcllaw.com klandau@tcllaw.com

Bradley J. Demuth FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Tel: (212) 983-9330 Fax: (212) 983-9331 bdemuth@faruqilaw.com

Counsel for Rochester Drug Cooperative, Inc. and the Proposed Direct Purchaser Class

Craig C. Reilly (VSB #20942) 111 Oronoco Street Alexandria, VA 22314 Telephone: (703) 549-5354 Fax: (703) 549-5355 Email: craig.reilly@ccreillylaw.com

Richard Alan Arnold (pro hac vice) Scott E. Perwin (pro hac vice) Lauren C. Ravkind (pro hac vice) Anna T. Neill (pro hac vice) Joshua B. Gray (pro hac vice) KENNY NACHWALTER P.A. Four Seasons Tower 1441 Brickell Avenue Suite 1100 Miami, FL 33131 Telephone: (305) 373-1000 Facsimile: (305) 372-1861 Email: sperwin@knpa.com

10

Local Counsel for Retailer Plaintiffs

#### Email: aneill@knpa.com

Counsel for Retailer Plaintiffs Walgreen Co., Kroger Co., Albertsons Companies, Inc., and HEB Grocery Company L.P. (No. 2:18-cv-266)

/s/ James A. Cales, III

Alan Brody Rashkind (VSB No. 12658) James A. Cales, III (VSB No. 41317) Furniss, Davis, Rashkind and Saunders, PC 6160 Kempsville Circle, Suite 341B Norfolk, Virginia 23502 757-461-7100 757-461-0083 (facsimile) ARashkind@furnissdavis.com JCales@furnissdavis.com

#### Liaison Counsel for the Proposed End-Payer Class

Marvin A. Miller Lori A. Fanning Miller Law LLC 115 S. LaSalle Street, Suite 2910 Chicago, IL 60603 Telephone: (312) 332-3400 <u>mmiller@MillerLawLLC.com</u> <u>Ifanning@millerlawllc.com</u> Michael M. Buchman Erin Durba Michelle C. Zolnoski Motley Rice LLC 600 Third Avenue, Suite 2101 New York, NY 10016 Telephone: (212) 577-0040 Facsimile: (212) 577-0054 mbuchman@motleyrice.com edurba@motleyrice.com mzolnoski@motleyrice.com

Co-Lead Counsel for the Proposed End-Payer Class

## /s/ Stephen E. Noona

Stephen E. Noona Virginia State Bar No. 25367 KAUFMAN & CANOLES, P.C. 150 W. Main Street, Suite 2100 Norfolk, VA 23510-1665 Tel.: (757) 624-3239 Fax: (888) 360-9092

#### SENoona@kaufcan.com

Liaison Counsel for Defendants Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., and MSP Singapore Co. LLC

> Samuel G. Liversidge (pro hac vice) Christopher D. Dusseault (pro hac vice) GIBSON, DUNN & CRUTCHER LLP 333 South Grand Avenue Los Angeles, CA 90071-3197 Tel.: (213) 229-7855 Fax: (213) 229-6855 SLiversidge@gibsondunn.com CDusseault@gibsondunn.com

Veronica S. Lewis (pro hac vice) GIBSON, DUNN & CRUTCHER LLP 2100 McKinney Avenue Dallas, TX 75201-6912 Tel.: (214) 698-3320 Fax: (214) 571-2936 VLewis@gibsondunn.com

Eric J. Stock (*pro hac vice*) GIBSON, DUNN & CRUTCHER LLP 200 Park Avenue New York, NY 10166-0193 Tel.: (212) 351-4000 Fax: (212) 351-4035 <u>EStock@gibsondunn.com</u>

Tarek Ismail (*pro hac vice*) Jennifer L. Greenblatt (*pro hac vice*) GOLDMAN ISMAIL TOMASELLI BRENNAN & BAUM LLP 564 West Randolph Street, Suite 400 Chicago, IL 60661 Telephone: (312) 681-6000 Facsimile: (312) 881-5191 <u>tismail@goldmanismail.com</u> jgreenblatt@goldmanismail.com

Counsel for Defendants Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., and MSP Singapore Co. LLC /s/ J. Kevin Fee

J. Kevin Fee (Bar. No. 88376) Teri J. Diaz (Bar. No. 87457) MORGAN, LEWIS & BOCKIUS LLP 1111 Pennsylvania Ave., NW Washington, D.C. 20005 Tel: 202.739.3000 Fax: 202.739.3001 kevin.fee@morganlewis.com teri.diaz@morganlewis.com

Liaison Counsel for Defendants Glenmark Pharmaceuticals, Ltd. and Glenmark Generics Inc., USA

Steven A. Reed (admitted *pro hac vice*) R. Brendan Fee (admitted *pro hac vice*) Zachary M. Johns (admitted *pro hac vice*) Jessica J. Taticchi (admitted *pro hac vice*) MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103 Tel: 215.963.5000 Fax: 215.963.5001 steven.reed@morganlewis.com brendan.fee@morganlewis.com jessica.taticchi@morganlewis.com

Stacey Anne Mahoney (admitted *pro hac vice*) MORGAN, LEWIS & BOCKIUS LLP 101 Park Ave. New York, NY 10178 Tel: 212.309.6000 Fax: 212.309.6001 stacey.mahoney@morganlewis.com

Counsel for Defendants Glenmark Pharmaceuticals, Ltd. and Glenmark Generics Inc., USA